Heron Therapeutics, Inc. beat EPS estimates 33% of the time across 3 reported quarters (1 beats, 2 misses). Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result |
|---|---|---|---|---|
| Q22026 FY2026 | $-0.02 | $-0.03 | -50.0% | Miss |
| Q12026 FY2026 | $-0.03 | $-0.04 | -33.3% | Miss |
| Q42025 FY2025 | $-0.03 | $-0.02 | +33.3% | Beat |
Back to HRTX overview · HRTX holders · HRTX KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.